Time from first symptom onset to the final diagnosis of multiple myeloma (MM) – possible risks and future solutions: retrospective and prospective ‘Deutsche Studiengruppe MM’ (DSMM) and ‘European Myeloma Network’ (EMN) analysis^*

References

• Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–e548.
   PubMed Web of Science ®Google Scholar
• Caers J, Fernández de Larrea C, Leleu X, et al. The changing landscape of smoldering multiple myeloma: a European perspective. Oncologist. 2016;21:333–342.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Cancer control: knowledge into action WHO guide for effective programmes – early detection; 2007 [cited 2019 Mar 2]. Available from: http://apps.who.int/iris/bitstream/10665/43743/1/9241547338_eng.pdf
   Google Scholar
• World Health Organization. Guide to cancer early diagnosis; 2017 [cited 2019 Mar 2]. Available from: http://apps.who.int/iris/bitstream/10665/254500/1/9789241511940-eng.pdf?ua=1
   Google Scholar
• Sonmez M, Akagun T, Topbas M, et al. Effect of pathologic fractures on survival in multiple myeloma patients: a case control study. J Exp Clin Cancer Res. 2008;27:11.
   PubMed Web of Science ®Google Scholar
• Melton LJ, Kyle RA, Achenbach SJ, et al. Fracture risk with multiple myeloma: a population-based study. J Bone Miner Res. 2004;20:487–493.
   PubMed Web of Science ®Google Scholar
• Engelhardt M, Herget GW, Graziani G, et al. Osteoprotective medication in the era of novel agents: a European perspective on values, risks and future solutions. Haematologica. 2018;103:755–758.
   PubMed Web of Science ®Google Scholar
• Mateos MV, Hernández MT, Giraldo P, et al. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. Lancet Oncol. 2016;17:1127–1136.
   PubMed Web of Science ®Google Scholar
• Koshiaris C, Oke J, Abel L, et al. Quantifying intervals to diagnosis in myeloma: a systematic review and meta-analysis. BMJ Open. 2018;8:e019758.
   PubMed Web of Science ®Google Scholar
• Lyratzopoulos G, Neal RD, Barbiere JM, et al. Variation in number of general practitioner consultations before hospital referral for cancer: findings from the 2010 National Cancer Patient Experience Survey in England. Lancet Oncol. 2012;13:353–365.
   PubMed Web of Science ®Google Scholar
• Lyratzopoulos G, Abel GA, McPhail S, et al. Measures of promptness of cancer diagnosis in primary care: secondary analysis of national audit data on patients with 18 common and rarer cancers. Br J Cancer. 2013;108:686–690.
   PubMed Web of Science ®Google Scholar
• Neal RD, Din NU, Hamilton W, et al. Comparison of cancer diagnostic intervals before and after implementation of NICE guidelines: analysis of data from the UK General Practice Research Database. Br J Cancer. 2014;110:584–592.
   PubMed Web of Science ®Google Scholar
• Kariyawasan CC, Hughes DA, Jayatillake MM, et al. Multiple myeloma: causes and consequences of delay in diagnosis. QJM. 2007;100:635–640.
   PubMed Web of Science ®Google Scholar
• Friese CR, Abel GA, Magazu LS, et al. Diagnostic delay and complications for older adults with multiple myeloma. Leuk Lymphoma. 2009;50:392–400.
   PubMed Web of Science ®Google Scholar
• Goldschmidt N, Zamir L, Poperno A, et al. Presenting signs of multiple myeloma and the effect of diagnostic delay on the prognosis. J Am Board Fam Med. 2016;29:702–709.
   PubMed Web of Science ®Google Scholar
• Mendonca SC, Abel GA, Saunders CL, et al. Pre-referral general practitioner consultations and subsequent experience of cancer care: evidence from the English Cancer Patient Experience Survey. Eur J Cancer Care. 2016;25:478–490.
   PubMed Web of Science ®Google Scholar
• Weller D, Vedsted P, Rubin G, et al. The Aarhus statement: improving design and reporting of studies on early cancer diagnosis. Br J Cancer. 2012;106:1262–1267.
   PubMed Web of Science ®Google Scholar
• Waldschmidt JM, Keller A, Ihorst G, et al. Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma). Haematologica. 2018;103:e473–e479.
   PubMed Web of Science ®Google Scholar
• Engelhardt M, Selder R, Pandurevic M, et al. [Multidisciplinary tumor boards: facts and satisfaction analysis of an indispensable comprehensive cancer center instrument]. Dtsch Med Wochenschr. 2017; 142:e51–e60. [German]
   PubMed Web of Science ®Google Scholar
• Gengenbach L, Reinhardt H, Ihorst G, et al. Navigating the changing multiple myeloma treatment landscape: clinical practice patterns of MM patients treated in- and outside German DSMM study group trials. Leukemia Lymphoma. 2018;59:2692–2699.
   PubMed Web of Science ®Google Scholar
• Engelhardt M, Ihorst G, Caers J, et al. Autotransplants in older multiple myeloma patients: hype or hope in the era of novel agents? Haematologica. 2016;101:1276–1278.
   PubMed Web of Science ®Google Scholar
• Engelhardt M, Domm AS, Dold SM, et al. A concise revised myeloma comorbidity index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica. 2017;102:910–921.
   PubMed Web of Science ®Google Scholar
• Cavo M, Rajkumar SV, Palumbo A, et al. International myeloma working group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood. 2011;117:6063–6073.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Rajkumar SV, San Miguel JF, et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. JCO. 2014;32:587–600.
   PubMed Web of Science ®Google Scholar
• Engelhardt M, Terpos E, Kleber M, et al. European myeloma network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica. 2014;99:232–242.
   PubMed Web of Science ®Google Scholar
• Auner HW, Szydlo R, Hoek J, et al. Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years. Bone Marrow Transplant. 2015;50:209–215.
   PubMed Web of Science ®Google Scholar
• Zweegman S, Engelhardt M, Larocca A. Elderly patients with multiple myeloma: towards a frailty approach? Curr Opin Oncol. 2017;29:315–321.
   PubMed Web of Science ®Google Scholar
• Larocca A, Dold SM, Zweegman S, et al. Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). Leukemia. 2018;32:1697–1712.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Stewart AK, Chanan-Khan A, et al. Smoldering multiple myeloma requiring treatment: time for a new definition? Blood. 2013;122:4172–4181.
   PubMed Web of Science ®Google Scholar
• Barlogie B, Mitchell A, Van Rhee F, et al. Curing myeloma at last: defining criteria and providing the evidence. Blood. 2014;124:3043–3051.
   PubMed Web of Science ®Google Scholar
• Howell DA, Smith AG, Jack A, et al. Time-to-diagnosis and symptoms of myeloma, lymphomas and leukaemias: a report from the haematological malignancy research network. BMC Hematol. 2013;13:9.
   PubMedGoogle Scholar
• König C, Kleber M, Ihorst G, et al. Prevalence of iron overload vs iron deficiency in multiple myeloma: resembling or different from MDS – and stem cell transplant (SCT) – patients? Clin Lymphoma Myeloma Leuk. 2013;13:671–680.
   PubMed Web of Science ®Google Scholar
• Deyo RA, Diehl AK. Cancer as a cause of back pain – frequency, clinical presentation, and diagnostic strategies. J Gen Intern Med. 1988;3:230–238.
   PubMed Web of Science ®Google Scholar
• Downie A, Williams CM, Henschke N, et al. Red flags to screen for malignancy and fracture in patients with low back pain: systematic review. BMJ. 2013;347:f7095–f7095.
   PubMed Web of Science ®Google Scholar
• Oliveira CB, Maher CG, Pinto RZ, et al. Clinical practice guidelines for the management of non-specific low back pain in primary care: an updated overview. Eur Spine J. 2018;27:2791–2803.
   PubMed Web of Science ®Google Scholar
• Crawford SC, Davis JA, Siddiqui NA, et al. The waiting time paradox: population based retrospective study of treatment delay and survival of women with endometrial cancer in Scotland. BMJ. 2002;325:196.
   PubMed Web of Science ®Google Scholar
• Raje N, Terpos E, Willenbacher W, et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol. 2018;19:370–381.
   PubMed Web of Science ®Google Scholar
• Koo MM, Hamilton W, Walter FM, et al. Symptom signatures and diagnostic timeliness in cancer patients: a review of current evidence. Neoplasia. 2018;20:165–174.
   PubMed Web of Science ®Google Scholar